Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MRK

Here's What to Expect From Merck & Co.'s Next Earnings Report

Merck & Co. is set to release its third-quarter earnings in a couple of weeks, and analysts are expecting its EPS to grow by a single digit.

Barchart · Oct 13

3 Healthcare Dividend Stocks Offering More Than Just Income

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

MarketBeat · Sep 30

This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%

Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.

Barchart · Sep 16

From analysis to the latest developments in health,
read the most diverse news in one place.

Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains

Coca-Cola, Chevron, and Merck have outperformed the S&P 500 in 2026, each pairing strong share-price gains with growing dividends backed by solid fundamentals.

MarketBeat · Sep 14

Is Merck Stock Outperforming the Nasdaq?

Merck has surged past the broader Nasdaq Composite over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

Barchart · Aug 30

Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.

JNJ, MRK, and AMGN use AI to speed drug discovery, beat the market, and pay dividends. See the top AI healthcare pick for 2026.

Barchart · Aug 28

Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)

Editor’s note: The ETFs data was updated and economic data was added

Benzinga · Aug 20

Read news from The Economist, FT, and more,
with one subscription

Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough

Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc. (NYSE:MRK) posted a major cancer-vaccine trial win.

Benzinga · Aug 20

Huge Unusual Put Options Volume in Merck - Is MRK Stock Overvalued?

A Barchart report shows that despite recent strong Q2 results and a 10% spike in Merck stock today, an unusually large volume of put options has traded at a much lower strike price. Is MRK stock overvalued?

Barchart · Aug 19

Earnings, PMI and Other Key Things to Watch this Week

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Barchart · Aug 2

Merck-Backed Lab Gets $8.5 Million to Fast-Track a Vaccine for a Rapidly Spreading Ebola Outbreak

Hilleman Laboratories, a Singapore-based joint venture of Merck & Co. Inc. (NYSE:MRK) MSD division and Wellcome, said Thursday it will develop and manufacture clinical trial doses of an investigational Bundibugyo Ebola vaccine with up to $8.5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

Benzinga · Jul 30

Earnings Preview: What To Expect From Merck & Co.'s Report

Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.

Barchart · Jul 14

This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026

Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.

Barchart · Jul 9

How to Buy Merck Stock for a 10% Discount or Achieve an 11% Annual Return

On Monday, with Merck trading at $119.60, the August put option with a strike price of $110 was trading around $2.03. Traders selling this put would receive $230 in option premium. In return for receiving this premium, they have an obligation to buy 100 shares of MRK for $110.

Barchart · Jun 24

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · May 29

Is Merck & Co. Stock Outperforming the S&P 500?

Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

MarketBeat · May 13

Merck KGaA Q1 Earnings Call Highlights

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

Barchart · May 4

Do Wall Street Analysts Like Merck & Co. Stock?

Merck & Co. has outperformed the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

Barchart · Apr 15

This Merck (MRK) Stock Bullish Diagonal Trade Targets a Price of $130 by June 18

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Apr 9

Merck & Co.'s Quarterly Earnings Preview: What You Need to Know

Merck & Co. is expected to unveil its first-quarter results later this month, and analysts are projecting a triple-digit decline in profit.

MarketBeat · Mar 31

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

Barchart · Feb 24

How Is Merck & Co.'s Stock Performance Compared to Other Healthcare Stocks?

Despite Merck & Co.’s strong performance relative to its peers over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects

Barchart · Jan 30

Merck & Co. Stock Outlook: Is Wall Street Bullish or Bearish?

Merck & Co. has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

MarketBeat · Jan 19

3 “Forever Stocks” to Hold When the Market Won’t Sit Still

Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy

Barchart · Jan 6

Merck & Co.'s Q4 2025 Earnings: What to Expect

Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Barchart · Dec 9, 2025

These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now

Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.